

Special Issue

Emerging Predictive Biomarkers in Breast Cancer

Message from the Guest Editors

The treatment landscape of breast cancer has profoundly changed over the last few years with the approval of several new therapeutic options for both early-stage and advanced/metastatic disease. Much progress has been made in discerning the molecular pathology of breast cancer, leading to the identification of different molecular subtypes with distinct clinical-pathological characteristics and therapeutic vulnerabilities. Recently, new novel classes of therapeutic agents have emerged in clinical practice, including immune checkpoint inhibitors and antibody drug conjugates, but there is a lack of reliable predictive biomarkers for these agents, and in some cases, they are still used with a one-size-fits-all approach.

Furthermore, the use of circulating biomarkers, namely liquid biopsy, and novel PET tracers in indications is rapidly growing, offering the possibility of further innovating the patient selection process for novel breast cancer therapies. The aim of this Special Issue is to expand the current knowledge on the molecular, genetic and therapeutic landscape of breast cancer, with a particular focus on novel biomarkers that could have an impact on clinical practice.

Guest Editors

Dr. Giuseppina Rosaria Rita Ricciardi

Department of Oncohematology, Papardo Hospital, Messina, Italy

Dr. Maria Vita Sanò

Department of Medical Oncology, Humanitas Istituto Clinico Catanese, Misterbianco, Catania, Italy

Deadline for manuscript submissions

31 October 2025



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/239154

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).